Masoom Haider, MD, Author at Grand Rounds in Urology

Masoom Haider, MD

University of Toronto

Toronto, Ontario, Canada

Masoom Haider, MD, is a Professor of Medical Imaging at the University of Toronto in Ontario. He received his MD from the University of Ottawa and undertook additional training at the University of Toronto and the Cleveland Clinic Foundation. Dr. Haider focuses on prostate cancer localization with MRI using multiparametric approaches; radiologic pathologic correlation in prostate cancer, GU malignancies, and other abdominal and pelvic malignancies; and feature analysis of tumors for imaging biomarker validation and therapy response assessment. He has worked on establishing guidelines for the use of mpMRI for prostate cancer, including the PI-RADS standard for performance and interpretation of prostate mpMRI. Dr. Haider holds three patents on medical imaging technologies and has over 180 publications in peer-reviewed journals.

Disclosures:

Talks by Masoom Haider, MD

Current Clinical Utility of MRI and Multi-Modality Imaging

Posted by Masoom Haider, MD | Dec 2020

Masoom Haider, MD, Professor of Medical Imaging at the University of Toronto, discusses the clinical utility of multiparametric MRI (mpMRI) in prostate cancer diagnosis, noting current knowledge and practice gaps and highlighting key areas for future research. He explains that while the benefits of mpMRI in biopsy-naïve men at high risk of prostate cancer have been confirmed several times over and it is increasingly recommended prior to biopsy, mpMRI can still miss between 3 and 11% of clinically significant cancers, so some kind of follow-up strategy or safety net is needed. Dr. Haider then discusses the need for a quality assurance system, like PI-QUAL, to ensure that mpMRIs are correctly performed and interpreted, as well as the need for a directed pathway to create a better flow of patients from initial assessment through to follow-up. He also briefly summarizes research on the comparative risks of lesions visible on mpMRI to lesions invisible on mpMRI, reducing mpMRI through better risk stratification, and comparing cancer detection with mpMRI to cancer detection with 68Ga-PSMA PET/CT. He concludes that a great deal remains to be learned both about the long term implications of using mpMRI and about the best ways to use it.

Multi-Parametric MRI

Posted by Masoom Haider, MD | Dec 2019

Masoom Haider, MD, provides an overview of the current state of multiparametric MRI, especially in the setting of biopsy-naive patients with elevated PSA levels. He then describes an MRI-directed biopsy pathway and how to integrate it into prostate cancer care.